Nathan M. Denlinger, DO, MS
Assistant Professor
Division of Hematology
The Ohio State University College of Medicine
Columbus, OH
This article is part 2 of a 2-part series from a Case-Based Roundtable event.
Targeted Oncology: What are the primary toxicities with chimeric antigen receptor (CAR) T-cell therapy in large B-cell lymphoma (LBCL), based on the ZUMA-7 trial (NCT03391466) and TRANSFORM trial (NCT03575351)?
Nathan M. Denlinger, DO, MS:CRS [(cytokine release syndrome) leads to fevers and can] look like they have sepsis. We deal with this inpatient [in tertiary care centers]. It’s not something [referring oncologists] will ever see, but it is something that affects patients significantly. Severe CRS was present in 6% of patients with axicabtagene ciloleucel [axi-cel; Yescarta] and 1% in lisocabtagene maraleucel…